Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

NCT03382886 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped PI decided to terminate due to low/slow accrual

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Bevacizumab

Sponsor

University of Utah

Collaborators

[object Object]